BMS gets US approval for ROS1 lung cancer drug Augtyro

Bristol-Myers Squibb has secured FDA approval for Augtyro, a lung cancer therapy it acquired as part of its $4.1 billion takeover of Turning Point Therapeutics last year that it hopes will challenge rival drugs from Roche and Pfizer.